What is the principle of using maternal blood cell tests to screen for thalassemia?

In general, the principle of prenatal thalassemia screening through blood cell analysis in pregnant women involves drawing a blood sample from the expectant mother and analyzing its components to assess whether the fetus may have thalassemia. The specific details are as follows:

Thalassemia is a genetic disorder. If direct blood relatives in the family have this condition, an individual may be a carrier and has a certain probability of passing it on, typically due to congenital genetic defects. Prenatal blood cell testing for thalassemia refers to analyzing the pregnant woman's blood to determine whether the fetus might be affected by thalassemia, and this screening is generally performed between 4–6 weeks of pregnancy. Blood cell examination includes tests such as complete blood count, blood typing, liver function, and kidney function, which help identify whether the pregnant woman suffers from iron-deficiency anemia, thalassemia, megaloblastic anemia, or other similar conditions. Additionally, pregnant women with thalassemia may experience certain complications and could pass the condition on to their offspring. It is recommended that pregnant women diagnosed with thalassemia receive genetic counseling and undergo regular prenatal check-ups during pregnancy to ensure healthy outcomes and reproductive health.

Pregnant women are advised to have regular medical check-ups at the hospital. If there are no obvious symptoms or only mild symptoms, special treatment is usually not required. However, if the condition is severe, and considering the risk of genetic transmission to the fetus, individuals should consult their doctor for professional advice and make informed personal decisions based on their specific circumstances.